Patents by Inventor Thomas W. Dubensky

Thomas W. Dubensky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid mucosal immunization
    Publication number: 20030021766
    Abstract: Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described are compositions comprising a mucosal adjuvant and one or more antigens derived from HIV. Also provided is the use of these gene delivery vehicles in inducing mucosal, local and/or systemic immune responses following mucosal immunization regimes.
    Type: Application
    Filed: January 14, 2002
    Publication date: January 30, 2003
    Inventors: Michael Vajdy, John Polo, Thomas W. Dubensky, Derek O'Hagan
  • Functional lentiviral vector from an MLV-based backbone
    Publication number: 20030003565
    Abstract: Disclosed are gene therapy vectors based on chimeric murine leukemia virus-feline immunodeficiency virus gene therapy vectors which are suitable for a wide variety of gene therapy applications. Also disclosed are related packaging cell lines, methods for production, and methods of use.
    Type: Application
    Filed: November 27, 2001
    Publication date: January 2, 2003
    Inventors: Thomas W. Dubensky, Mehdi Gasmi, Sybille Sauter
  • Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
    Patent number: 6465634
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: October 15, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
  • Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
    Patent number: 6458560
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: October 1, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilva Frolov
  • Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
    Patent number: 6451592
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: September 17, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
  • Alphavirus structural protein expression cassettes
    Patent number: 6426196
    Abstract: Isolated nucleic acid molecules are disclosed. comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: July 30, 2002
    Assignees: Chiron Corporation, Washingto University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Sondra Schlesinger, Ilya Frolov
  • Feline immunodeficiency virus gene therapy vectors
    Publication number: 20020068354
    Abstract: Disclosed are gene therapy vectors based upon the feline immunodeficiency virus, as well as related packaging cell lines, methods for production, and methods of use.
    Type: Application
    Filed: March 1, 2001
    Publication date: June 6, 2002
    Applicant: CHIRON CORPORATION
    Inventors: Julie C. Johnston, Sybille L. Sauter, David Chi-Tang Hsu, Philip Lee Sheridan, Stephen F. Hardy, Thomas W. Dubensky, Jiing-Kuan Yee
  • Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
    Patent number: 6391632
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as is compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: May 21, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
  • FELINE IMMUNODEFICIENCY VIRUS GENE THERAPY VECTORS
    Publication number: 20020048805
    Abstract: Disclosed are gene therapy vectors based upon the feline immunodeficiency virus, as well as related packaging cell lines, methods for production, and methods of use.
    Type: Application
    Filed: January 15, 1999
    Publication date: April 25, 2002
    Inventors: JULIE C. JOHNSTON, SYBILLE L. SAUTER, DAVID CHI-TANG HSU, PHILIP LEE SHERIDAN, STEPHEN F. HARDY, THOMAS W. DUBENSKY, JIING-KUAN YEE
  • Recombinant alphavirus particles
    Patent number: 6376236
    Abstract: Disclosed are recombinant alphavirus particles comprising a) an alphavirus vector construct which directs the expression of a heterologous nucleic acid molecule; b) a capsid protein; and c) an envelope glycoprotein from a virus different from said alphavirus vector.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: April 23, 2002
    Assignee: Chiron Corporation
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Carlos E. Ibanez, David A. Driver
  • Methods of transducing neural cells using lentivirus vectors
    Publication number: 20020037281
    Abstract: Gene delivery vectors, such as, for example, recombinant FIV vectors, and methods of using such vectors are provided for use in transducing neural cells, such as neural progenitor cells, and cerebellar neurons, in particular, Purkinje cells.
    Type: Application
    Filed: May 25, 2001
    Publication date: March 28, 2002
    Inventors: Beverly L. Davidson, Joseph M. Alisky, Thomas W. Dubensky, Stephanie M. Hughes, Douglas Jolly, Sybille L. Sauter
  • Method for the purification of alphavirus replicon particles
    Publication number: 20020015945
    Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.
    Type: Application
    Filed: May 31, 2001
    Publication date: February 7, 2002
    Inventors: John M. Polo, Catherine Greer, Maria Calderon-Cacia, Daniel Del La Vega, Thomas W. Dubensky
  • Eukaryotic layered vector initiation systems for production of recombinant proteins
    Patent number: 6342372
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: January 29, 2002
    Assignee: Chiron Corporation
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, David A. Driver
  • Compositions and methods for packaging of alphavirus vectors
    Patent number: 6329201
    Abstract: Nucleic acid molecule are provided comprising a nucleic acid sequence which encodes, in order, an alphavirus capsid, a signal peptide, and an alphavirus E1 or E2 glycoprotein. Also provided are vectors encoding such nucleic acid molecules, and use of such vectors or expression cassettes to generate recombinant alphavirus particles and alphavirus packaging cell lines. In addition, modified alphavirus vector constructs are provided that permit reduced transgene expression during vector packaging, as well as methods of using such vector constructs for the production of alphavirus vector particles.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: December 11, 2001
    Assignee: Chiron Corporation
    Inventors: John M. Polo, Thomas W. Dubensky, Jr., Stephen F. Hardy, Silvia Perri
  • Compositions and methods for packing of alphavirus vectors
    Patent number: 6242259
    Abstract: Nucleic acid molecule are provided comprising a nucleic acid sequence which encodes, in order, an alphavirus capsid, a signal peptide, and an alphavirus E1 or E2 glycoprotein. Also provided are vectors encoding such nucleic acid molecules, and use of such vectors or expression cassettes to generate recombinant alphavirus particles and alphavirus packaging cell lines. In addition, modified alphavirus vector constructs are provided that permit reduced transgene expression during vector packaging, as well as methods of using such vector constructs for the production of alphavirus vector particles.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: June 5, 2001
    Assignee: Chiron Corporation
    Inventors: John Polo, Barbara Beli, Thomas W. Dubensky, Jr., Stephen F. Hardy, Silvia Perri
  • Method for stimulating an immune response utilizing recombinant alphavirus particles
    Patent number: 6015694
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: January 18, 2000
    Assignee: Chiron Corporation
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Steven M.W. Chang, Douglas J. Jolly
  • Eukaryotic layered vector initiation systems
    Patent number: 6015686
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: January 18, 2000
    Assignee: Chiron Viagene, Inc.
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Douglas J. Jolly, David A. Driver
  • Alphavirus vector constructs
    Patent number: 5843723
    Abstract: The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: December 1, 1998
    Assignee: Chiron Corporation
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Carlos E. Ibanez, Stephen M. W. Chang, Douglas J. Jolly, David A. Driver, Barbara A. Belli
  • Eukaryotic layered vector initiation systems
    Patent number: 5814482
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: September 29, 1998
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Douglas J. Jolly, David A. Driver
  • Alphavirus structural protein expression cassettes
    Patent number: 5789245
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: August 4, 1998
    Assignee: Chiron Corporation
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Carlos E. Ibanez, Stephen M. W. Chang, Douglas J. Jolly, David A. Driver